Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension

This study has been withdrawn prior to enrollment.
(due to lack of finance)
Sponsor:
Information provided by:
Herlev Hospital
ClinicalTrials.gov Identifier:
NCT00506701
First received: July 23, 2007
Last updated: February 25, 2010
Last verified: July 2007

July 23, 2007
February 25, 2010
February 2008
February 2010   (final data collection date for primary outcome measure)
Change in 6 min. walking test [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Change in 6 min. walking test [ Time Frame: 6 months ]
Complete list of historical versions of study NCT00506701 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension
Pilot Study to Investigate the Effect of Tadalafil on Secondary Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease

Tadalafil may lower the pulmonary artery pressure in patients with Chronic Obstructive Lung Disease and secondary pulmonary hypertension and thereby improve patients quality of life.

Twenty outpatients with Chronic Obstructive Lung Disease (COPD) and secondary pulmonary hypertension are treated in a cross-over design with Tadalafil or placebo for 4 weeks. Primary effect parameter is 6 min. walking test.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Chronic Obstructive Lung Disease
Drug: Tadalafil
40 mg tablet
Other Name: PDE5 inhibitor
Experimental: Tadalafil treatment 40 mg
Intervention: Drug: Tadalafil
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
20
February 2010
February 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of Chronic obstructive lung disease

Exclusion Criteria

  • Patients with asthma
Both
45 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT00506701
25
Yes
Lars C. Laursen, Herlev Hospital
Herlev Hospital
Not Provided
Principal Investigator: Lars C Laursen, MD University of Copenhagen
Herlev Hospital
July 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP